Abstract:Abstract Background Nintedanib, an FDA approved triple tyrosine kinase inhibitor, exhibits an antifibrotic effect in idiopathic pulmonary and renal fibrosis. Its effect on peritoneal fibrosis remains unexplored. Methods The present study investigated the effect of nintedanib on the development and progression of peritoneal fibrosis by administration fo nintedanib immediately after peritoneal injury or starting at day 21 of the injury in a in a mouse model of chlorhexidine gluconate-induced peritoneal fibrosis. Peritoneal fibrosis and associated mechanisms were examined by immunohistochemistry and immunoblot analysis. Results Administration of nintedanib immediately after peritoneal injury attenuated peritoneal fibrosis, whereas delayed administration of nintedanib not only halted the progression of peritoneal fibrosis, but also in part reversed the established fibrosis. Mechanistically studies showed that nintedanib inhibited injury-induced mesothelial-to-mesenchymal transition, expression of several cytokines/chemokines, vascularization and infiltration of macrophages to the injured peritoneum. Nintedanib also blocked phosphorylation of platelet derived growth factor receptor, fibroblast growth factor receptor, vascular endothelial growth factor receptor, and Src, downregulated expression of Snail and Twist, two transcription factors and inactivated several signaling pathways associated with peritoneal fibrosis, including Smad3, signal transducer and Activator of transcription 3, and nuclear factor-κB. Moreover, late treatment with nintedanib promoted expression of matrix metallopeptidase 2 and reduced expression of tissue inhibitor of metalloproteinases 2 in the injured peritoneum. Finally, nintedanib abrogated transforming growth factor β1–induced mesothelial-to-mesenchymal transition and phosphorylation of aforementioned signaling molecules in cultured human peritoneal mesothelial cells. Conclusions These results suggest that nintedanib may inhibit peritoneal fibrosis development and progression by blocking mesothelial-to-mesenchymal transition, inflammation, and angiogenesis, and partially reversed established peritoneal fibrosis through metalloproteinases-mediated extracellular matrix degradation. Therefore, nintedanib holds therapeutic potential for the prevention and treatment of peritoneal fibrosis.

Nintedanib, a multitarget tyrosine kinase inhibitor, suppresses postoperative peritoneal adhesion formation in a rat model

The Inhibitory Effects of Naringin in a Rat Model of Postoperative Intraperitoneal Adhesion Formation

Nintedanib inhibits the development and progression of peritoneal fibrosis

Nintedanib Attenuates Peritoneal Fibrosis by Inhibiting Mesothelial-To-Mesenchymal Transition, Inflammation and Angiogenesis

Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model

Paeoniflorin prevents postoperative peritoneal adhesion formation in an experimental rat model.

Effect of Resveratrol on the Prevention of Intra-Abdominal Adhesion Formation in a Rat Model

Preventive Effects of the Intestine Function Recovery Decoction, a Traditional Chinese Medicine, on Postoperative Intra-Abdominal Adhesion Formation in a Rat Model

Pharmacological HIF-inhibition attenuates postoperative adhesion formation

The experimental study of the anti-adhesion effects of nanofiber membranes on the prevention of postoperative intra-abdominal adhesion

Danhong Injection Alleviates Postoperative Intra-abdominal Adhesion in a Rat Model

Intraperitoneal Lavage with Crocus sativus Prevents Postoperative-Induced Peritoneal Adhesion in a Rat Model: Evidence from Animal and Cellular Studies

Effects of linalool on postoperative peritoneal adhesions in rats

D-limonene inhibits peritoneal adhesion formation in rats via anti-inflammatory, anti-angiogenic, and antioxidative effects

Effect of ligustrazine nanoparticles on Th1/Th2 balance by TLR4/MyD88/NF-κB pathway in rats with postoperative peritoneal adhesion

Comparing Intraperitoneal Adhesion by various Lipid compounds in a Rat Model

Nintedanib, a Triple Tyrosine Kinase Inhibitor, Attenuates Renal Fibrosis in Chronic Kidney Disease.

Tanshinone IIA Attenuates Peritoneal Fibrosis Through Inhibition of Fibrogenic Growth Factors Expression in Peritoneum in a Peritoneal Dialysis Rat Model

The protective effects of keratinocyte growth factor targeted mesothelium on the postoperative peritoneal adhesions

Investigation of the effects of different drugs on the prevention of intrapleural adhesion in a rat model

Antifibrotic Role of Nintedanib in Tracheal Stenosis after a Tracheal Wound